Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07358572
Recruiting Observational

Eye-Brain-Kidney in CKD

NCT07358572 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Friendship Hospital
Phase
Observational
Started
2025-12-01
Last updated
2026-01-27

Condition(s) studied

Chronic Kidney Diseases

Study summary

The goal of this observational study is to learn about the interaction between the eyes, brain, and kidneys in adult patients with Chronic Kidney Disease (CKD). The main question it aims to answer is:

Do changes in the brain's network connectivity and the retina's blood vessels correlate with cognitive decline and kidney function in CKD patients? Participants with CKD who are already undergoing clinical care will complete cognitive tests and questionnaires, have non-invasive MRI scans of their brain and kidneys, and undergo non-invasive eye imaging (OCT/OCTA) of their retinas.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. Aged 18-70 years. 2. Patients clinically diagnosed with CKD stages 1-5. 3. No contraindications for MRI examination (e.g., cardiac pacemaker, claustrophobia, cochlear implant, hearing aid, coronary stents implanted before 2015) and able to complete the MRI scan. Exclusion Criteria: 1. Patients with recent or prior cerebral hemorrhage or cerebral infarction. 2. History of epileptic seizures or psychiatric disorders. 3. Patients with claustrophobia. 4. Pregnant or lactating patients. 5. Presence of other central nervous system diseases (e.g., tumor, trauma). 6. Unstable angina, congestive heart failure (NYHA class III or IV), or acute myocardial infarction. 7. Any systemic or other diseases deemed unsuitable for clinical trial participation.

Primary outcome measure(s)

  • Cognitive function assessed by Montreal Cognitive Assessment (MoCA) — Baseline and 3-year follow-up.
    The Montreal Cognitive Assessment (MoCA) is a cognitive screening tool with a total score range of 0 to 30, where higher scores indicate better cognitive function. A score below 26 is indicative of cognitive impairment.

Trial sites (1)

FacilityCityRegionStatus
Beijing Friendship Hospital, Capital Medical University Beijing Beijing Municipality Recruiting

More Beijing Friendship Hospital trials in China

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity Starting soon
Rivaroxaban in Idiopathic Membranous Nephropathy Recruiting
Adverse Cardiovascular Events During Painless Gastroscopy Diagnosis and Treatment in Elderly Frail Patients Recruiting
Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections Starting soon
Clinical Indicators and Brain Image Data: a Study Based on Kailuan Cohort Recruiting

Other trials for the same condition

The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome Recruiting
Integrated Diagnosis and Treatment of CKD on Outcomes Recruiting
A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male Subjects Starting soon
Uremic Toxins and Outcomes in Chronic Kidney Disease Recruiting
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07358572 on ClinicalTrials.gov ↗ ← All trials in China